Incyte reports positive Phase 3 data for Zynyz for lung cancer (NASDAQ:INCY)

Incyte reports positive Phase 3 data for Zynyz for lung cancer (NASDAQ:INCY)

Incyte (INCY) reported positive results from a Phase 3 study of its drug Zynyz in the treatment of non-small cell lung cancer, or NSCLC. Read more here.

Repurposed drug has promising efficacy in non-small cell lung cancer

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed.

Repurposed drug has promising efficacy in non-smal

An FDA-approved drug used to treat multiple myeloma and lymphoma also shrank tumors in non-small cell lung cancer (NSCLC) with KRAS mutations, a clinical trial led by UT Southwestern Harold C. Simmons Comprehensive Cancer Center researchers showed. The findings, published in Clinical Cancer Research, a journal of the American Association for Cancer Research, could lead to new treatments for a major subset of lung cancer patients.